Chiglitazar Added to Metformin for Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 533 participants.
Also called NCT04807348
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 533 participants
- Sponsor
- Registry
-
NCT04807348
-
- Other papers using this trial's data
- Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)
- Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study)
- Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04807348. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-06 (actual); primary completion 2023-02-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Chiglitazar Added to Metformin for Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Chiglitazar 32mg
- Intervention (Drug)
- Chiglitazar 48mg
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin Hydrochloride
- Lead sponsor
- Chipscreen Biosciences, Ltd.
Record details
- Record id
cardio:ct-nct04807348- Content hash
77556d3facd940aceb2c02fe049835b18e543ecc229c3fc5408bd1cd0242e04f